Woodline Partners LP Autolus Therapeutics PLC Transaction History

Woodline Partners LP

  • $11 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$2.04 - $3.76 $607,632 - $1.12 Million
-297,859 Reduced 41.02%
428,255 $916,000
Q2 2022

Aug 15, 2022
SELL
$2.04 - $4.68 $142,589 - $327,117
-69,897 Reduced 8.78%
726,114 $2.06 Million
Q1 2022

May 16, 2022
SELL
$3.52 - $5.46 $499,664 - $775,047
-141,950 Reduced 15.13%
796,011 $3.32 Million
Q4 2021

Feb 14, 2022
BUY
$5.1 - $7.0 $4.78 Million - $6.57 Million
937,961 New
937,961 $4.87 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email